biote (BTMD) Projected to Post Earnings on Wednesday

biote (NASDAQ:BTMD) is projected to announce its Q4 2025 results after the market closes on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $45.79 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 5:00 PM ET.

biote Stock Performance

BTMD stock opened at $2.11 on Wednesday. The company has a market capitalization of $96.34 million, a P/E ratio of 2.67 and a beta of 1.14. The company has a fifty day moving average price of $2.29 and a 200-day moving average price of $2.70. biote has a 52-week low of $2.02 and a 52-week high of $4.75.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. B. Riley Financial reaffirmed a “neutral” rating on shares of biote in a research report on Thursday, November 6th. Truist Financial set a $5.00 price target on biote in a research note on Wednesday, January 7th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of biote in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.67.

Institutional Investors Weigh In On biote

Several large investors have recently added to or reduced their stakes in the business. Rothschild Wealth LLC bought a new stake in biote in the fourth quarter worth approximately $380,000. WINTON GROUP Ltd acquired a new stake in shares of biote during the 3rd quarter worth approximately $309,000. State Street Corp increased its stake in shares of biote by 17.3% in the 4th quarter. State Street Corp now owns 600,114 shares of the company’s stock valued at $1,560,000 after acquiring an additional 88,402 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in shares of biote by 142.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock valued at $487,000 after acquiring an additional 71,053 shares during the period. Finally, Man Group plc boosted its stake in biote by 419.1% during the second quarter. Man Group plc now owns 64,027 shares of the company’s stock worth $257,000 after acquiring an additional 51,693 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.